Loading stock data…
ZYME
$26.61-0.93 (-3.38%)
Market ClosedLast close May 1
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zymeworks Inc. in the Healthcare sector is trading at $26.61. The stock is currently near its 52-week high of $29.75, remaining 26.4% above its 200-day moving average. Technical signals show neutral RSI of 53 and bearish MACD signal, explaining why ZYME maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 53) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$26.61
Potential Upside
5%
Whystock Fair Value$27.94
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Mean target$40.08+50.6%
Range$31.00 – $58.00
Fundamentals
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a s...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.00B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-30.22%
Volume
Today's trading volume
345,119
Recent News
April 2026's Top 3 Stocks That May Be Trading Below Estimated Fair Value
Over the last 7 days, the United States market has remained flat, yet it has experienced a significant 30% increase over the past year with earnings projected to grow by 16% annually. In this environment, identifying stocks that may be trading below their estimated fair value can present opportunities for investors seeking potential long-term gains.
Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar Ziihera
Zymeworks (NASDAQ:ZYME) used a presentation at the Bloom Burton conference to outline how the company is repositioning itself around its first approved product and a growing stream of royalty and milestone revenue, while continuing to invest in internal research and development across antibody-drug
Capricorn Fund Managers Dumps $18.4 Million Worth of Waystar Stock in Q1
Waystar delivers cloud-based payment solutions for healthcare providers, supporting over $1 billion in annual revenue with a SaaS model.
How Investors May Respond To Zymeworks (ZYME) Hiring EcoR1 Executives To Lead R&D And Deals
Zymeworks Inc. recently confirmed that, effective April 9, 2026, it appointed Dr. Adam Schayowitz as Executive Vice President and Head of Research & Development and Mr. Scott Platshon as Executive Vice President and Chief Business Officer, both joining full-time from key shareholder EcoR1 Capital to lead R&D and business operations. This move brings deeper oncology drug development and business development expertise directly into the company as it advances its clinical portfolio and manages...
Jazz Pharmaceuticals Touts Record $4.3B 2025 Revenue, Reaffirms 2026 Outlook at Conference
Jazz Pharmaceuticals (NASDAQ:JAZZ) executives highlighted record 2025 revenue, a growing pipeline anchored by oncology programs, and a refined strategy emphasizing rare diseases during a conference session featuring Chief Financial Officer Philip Johnson and investor relations leaders Jack Spinks an